Personalized RNA Neoantigen Vaccine Stimulate Powerful T-Cell Responses in Pancreatic Cancer
Autogene Cevumeran, an individualized uridine mRNA–lipoplex nanoparticle vaccine, was developed to target pancreatic ductal adenocarcinoma (PDAC). In a phase I clinical study, the vaccine was found to be feasible, tolerable, and capable of generating strong antitumor immune responses in patients with surgically resected PDAC. Among vaccinated patients, 50% developed high-magnitude, neoantigen-specific T-cell responses, including functional CD8+ T cells that persisted for up to two years and re-expanded after a booster dose. Importantly, responders experienced longer recurrence-free survival, supporting further investigation of autogene cevumeran as a strategy to delay pancreatic cancer recurrence.










